Invokanacanagliflozin
According to the FDA label: INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).
29,639 adverse event reports submitted to the FDA (2011–2026)
Top Reported Adverse Events
The most frequently reported events in association with Invokana in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Diabetic Ketoacidosis 3,423 reports
A serious complication of diabetes where the blood becomes too acidic, needing urgent medical care.
Full definition in the glossary →- Toe Amputation 2,195 reports
- Osteomyelitis 2,165 reports
Acute Kidney Injury 1,994 reports
A sudden drop in how well the kidneys are working. It is often temporary and can have many causes.
Full definition in the glossary →- Fungal Infection 1,447 reports
Weight Decreased 1,341 reports
Blood Glucose Increased 1,232 reports
A blood test result showing a higher than normal blood sugar level.
Full definition in the glossary →- Gangrene 1,084 reports
- Cellulitis 1,035 reports
Urinary Tract Infection 1,018 reports
An infection in the bladder, urethra, or kidneys, often called a UTI.
Full definition in the glossary → See all drugs reporting this event →Nausea 1,009 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →Off Label Use 1,008 reports
Using a medication for a condition or in a way that the FDA has not officially approved. This is common and often legal, and a report of it does not mean something went wrong. Doctors sometimes prescribe drugs off label based on their judgment.
Full definition in the glossary →Drug Ineffective 1,006 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →Dizziness 841 reports
A feeling of being lightheaded, unsteady, or like the room is spinning.
Full definition in the glossary → See all drugs reporting this event →- Diabetic Foot Infection 834 reports
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Male | 13,393 |
| Female | 12,769 |
| Unknown | 47 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 872 |
| 18-34 | 499 |
| 35-49 | 3,155 |
| 50-64 | 7,955 |
| 65-74 | 3,488 |
| 75+ | 1,458 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Invokana. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Hospitalization | 10,652 |
| Non-Serious | 10,476 |
| Other Serious | 10,339 |
| Disability | 1,301 |
| Life-Threatening | 1,106 |
| Death | 682 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Invokana. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 246 |
| 2014 | 984 |
| 2015 | 7,889 |
| 2016 | 4,292 |
| 2017 | 4,362 |
| 2018 | 4,643 |
| 2019 | 2,386 |
| 2020 | 1,464 |
| 2021 | 825 |
| 2022 | 811 |
| 2023 | 690 |
| 2024 | 503 |
| 2025 | 470 |
| 2026 (partial) | 68 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Invokana
In FDA adverse event reports that mention Invokana, these medications appeared most often in the same report.
- Metformin (7,393 reports)
- Insulin Glargine (2,126 reports)
- Lisinopril (1,674 reports)
- Aspirin (1,623 reports)
- Sitagliptin (1,338 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026